Syensqo launches strategic review of Performance and Care segment in major portfolio reset
By: ICN Bureau
Last updated : May 23, 2026 1:38 pm
The review is aimed at tightening the company’s focus on its strongest growth engines and maximizing shareholder value
Syensqo has announced a strategic review of its Performance and Care segment, signalling a sharper pivot toward becoming a pure-play specialty materials and advanced technologies company.
The move underscores a broader effort to streamline the company’s portfolio and concentrate on higher-margin, innovation-driven businesses such as aerospace and defence, electronics, healthcare, energy, and advanced mobility.
“Since the start of the year, and along with the Board, we have undertaken a strategic assessment of our long-term direction and value creation priorities. In addition, we are fully focused on accelerating our growth trajectory, driving more consistent execution, sharpening our capital discipline as well as improving cash flow delivery,” said Mike Radossich, Chief Executive Officer of Syensqo.
He added that the review is aimed at tightening the company’s focus on its strongest growth engines and maximizing shareholder value.
“Today’s announcement reflects our intention to further sharpen our portfolio, increase our focus on technologies where we see the strongest long-term growth opportunities and drive sustained, innovation-led differentiation. Accordingly, we will now evaluate a range of strategic options for the Performance & Care segment, with an emphasis on maximizing long-term value for our shareholders.”
The company said there is no fixed timeline for the review and cautioned that it may not result in any transaction, nor any certainty around structure or terms if a deal proceeds.
The Performance & Care segment—which includes the Novecare and Technology Solutions business units—is a global leader in surface chemistry solutions and specialty mining reagents, serving consumer care, agro, coatings, and mining markets. In 2025, it generated €2.0 billion in net sales and €358 million in underlying EBITDA.